Cited 17 times in
Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 라선영 | - |
dc.contributor.author | 정현철 | - |
dc.contributor.author | 정희철 | - |
dc.contributor.author | 노재경 | - |
dc.date.accessioned | 2014-12-21T16:29:03Z | - |
dc.date.available | 2014-12-21T16:29:03Z | - |
dc.date.issued | 2007 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/95778 | - |
dc.description.abstract | BACKGROUND: The purpose of this study was to evaluate the tolerability and efficacy of irofulven, a DNA interacting acylfulvene analog, as first line therapy for patients with recurrent or metastatic gastric cancer. PATIENTS AND METHODS: Twenty-three patients with recurrent or metastatic gastric cancer received irofulven at a dose of 0.45 mg/kg administered intravenously over 30-min infusion (up to a maximum of 50 mg), on days 1 and 8, every 3 weeks. RESULTS: The median number of cycles delivered per patient was 2 (range 1-6). Two patients (9%) had >or= 1-week delay in administration of subsequent cycle of chemotherapy. For the day 8 chemotherapy, dose reductions were required in seven patients (30%); dose omitting occurred in five patients (22%). Grade 3/4 anemia and neutropenia occurred in 22 and 17% of patients, respectively. There was no grade 4 thrombocytopenia and no neutropenic fever was observed. Of the 20 evaluable patients, there were no responses observed, 3 patients had stable disease after 2 cycles of treatment which was not confirmed by a further assessment. Median overall survival was 6.05 months (95% CI 4.55-9.39). CONCLUSIONS: Irofulven was tolerated at the dose of 0.45 mg/kg on days 1 and 8, every 3 weeks but showed no evidence of antitumor activity in patients with advanced gastric cancer. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 295~300 | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | W. Yeo | - |
dc.contributor.googleauthor | M. Boyer | - |
dc.contributor.googleauthor | A. T. C. Chan | - |
dc.contributor.googleauthor | B. C. Goh | - |
dc.contributor.googleauthor | R. Soo | - |
dc.contributor.googleauthor | H. C. Jeung | - |
dc.contributor.googleauthor | S. Y. Rha | - |
dc.contributor.googleauthor | P. Beale | - |
dc.contributor.googleauthor | J. K. Roh | - |
dc.contributor.googleauthor | S. Clarke | - |
dc.contributor.googleauthor | R. Ho | - |
dc.contributor.googleauthor | E. K. W. Ng | - |
dc.contributor.googleauthor | F. K. F. Mo | - |
dc.contributor.googleauthor | K. C. Lam | - |
dc.contributor.googleauthor | B. Ma | - |
dc.contributor.googleauthor | Benny Zee | - |
dc.contributor.googleauthor | R. Lim | - |
dc.contributor.googleauthor | S. Y. K. Ong | - |
dc.contributor.googleauthor | H. C. Chung | - |
dc.identifier.doi | 10.1007/s00280-006-0270-1 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03773 | - |
dc.contributor.localId | A01290 | - |
dc.contributor.localId | A01316 | - |
dc.contributor.localId | A03794 | - |
dc.relation.journalcode | J00437 | - |
dc.identifier.eissn | 1432-0843 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs00280-006-0270-1 | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.alternativeName | Jeung, Hei Cheul | - |
dc.contributor.alternativeName | Roh, Jae Kyung | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Roh, Jae Kyung | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | Jeung, Hei Cheul | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 59 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 295 | - |
dc.citation.endPage | 300 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.59(3) : 295-300, 2007 | - |
dc.identifier.rimsid | 51541 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.